Posted By Dr.-Mercola | April 17 2012
Story at-a-glance
- A
new study showed that 81 percent of 2010 California B. pertussis
whooping cough cases in people under the age of 18 occurred in those,
who were fully up to date on the whooping cough vaccine (compared to 8
percent who had never been vaccinated)
- The
whole cell pertussis vaccine (DPT) and the newer acellular pertussis
vaccine (DTaP), which is now used in the U.S., are far from 100%
effective. In the featured study of DTaP vaccine, researchers noted the
vaccine’s effectiveness was only 41 percent among 2- to 7-year-olds and
a dismal 24 percent among those aged 8-12;
- The
DTaP study also suggested that the acellular pertussis (whooping
cough) vaccine loses much of its effectiveness after just three years.
This is much faster than previously believed, and is thought to be one
reason why there have been increases in whooping cough cases in the
U.S. in recent years
- There
is also evidence that the B. pertussis organism has evolved to evade
widespread use of pertussis vaccine, creating a new B. pertussis strain
that is not covered in the vaccine and is causing much more serious
disease, which is considered to be another reason why B. pertussis
whooping cough cases are on the rise
- Pertussis
vaccine in the combination DPT shot for diphtheria-tetanus-pertussis
that is supposed to prevent whooping cough has caused brain
inflammation, permanent brain damage and death in some children since it
was used on a mass basis in the U.S. starting in the late 1940s and
DTaP vaccine has also been associated with brain inflammation, permanent
brain damage and death, although it is thought to occur less
frequently than for whole cell DPT vaccine
FULL STORY
No comments:
Post a Comment